A Backstage View Of Roche’s Recent Collaborations
Deal-Making Activities Continue In Full Force Amid Coronavirus Chaos
Executive Summary
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
You may also be interested in...
Deal Watch: Coronavirus Collaborations Reflect Industry’s Full Press Pandemic Response
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
C4 Therapeutics Start-up Starts With Roche Tie-Up, $73m Series A
One of the decade's largest Series A financings for a biopharmaceutical start-up and a potentially lucrative collaboration with Roche mark the unveiling of C4 Therapeutics, which will work primarily with partners to develop what it calls Degronomids against targeted disease-causing proteins.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.